### Skin-picking behavior in a patient with schizoaffective disorder

#### John Edminister<sup>(1)</sup> Chandani Lewis, MD<sup>(2)</sup>

- (1) The University of Toledo College of Medicine and Life Sciences
- (2) The University of Toledo Medical Center, Department of Psychiatry Zepf Center, Staff Psychiatrist

#### Introduction

- Psychocutaneous disease represents the interface between the two medical specialties of dermatology and psychiatry.
- The differential diagnosis for skin-picking behavior includes skin-picking disorder, body dysmorphic disorder, delusions of parasitosis, and dermatitis artefacta. Skin-picking disorder (SPD) is a new diagnosis in the DSM-V.
- Research has found significant association between skin-picking and depression, bipolar disorder 1, eating disorders, generalized anxiety disorder, obsessive-compulsive disorder, and body dysmorphic disorders<sup>1-3</sup>. Significant impairment is observed in patients even after the comorbid psychiatric conditions are controlled.
- There is a paucity of information regarding skin-picking in psychotic disorders. In fact, psychotic disorders are an exclusion criteria in some studies and reviews on skin-picking.
- We report a case of a 34-year-old African-American male with 3 to 4 years of compulsive skin-picking alongside his diagnoses of schizoaffective disorder (depressive type) and alcohol use disorder. A constant theme of his derogatory auditory hallucinations is the cosmetic appearance of his excoriations and scars from picking.

# Purpose Using our case report:

- Recognize the importance of addressing skinpicking in patients with psychotic disorders. It causes significant distress and may be an unnoticed or unaddressed component of their mental health.
- Demonstrate the pitfalls of diagnosis and management of skin-picking behavior in patients with a psychotic disorder.
- Describe the neurotransmitter pathways and possible interventions in a patient with skinpicking with psychotic disorder.
- Discuss how skin-picking with comorbid psychotic disorders may be addressed in the future.


#### **Case Presentation**


- Our patient is a 34 year-old African-American male with a diagnosis of schizoaffective disorder (depressive type) and alcohol use disorder. The patient has a long history of mental illness and has been treated even before he presented to our Community Mental Health Center (CMHC) in 2015. His past medical history reveals use of various antipsychotics over the years, including haloperidol, olanzapine, and valproic acid. He has not been treated with an SSRI other than trazodone. His current medications are oral quetiapine 200 mg once daily and 1.5 mL of 234 mg/1.5 mL intramuscular paliperidone every 3 weeks, although his adherence to the trazadone is intermittent.
- The patient has a well-documented history of nonadherence to his oral medications.
- We reviewed the patient's chart and conducted an inperson interview to assess his skin-picking, which has been a daily problem for the last 3-4 years. He met the DSM-V criteria for SPD. After years of mental health treatments, the distress of his skin-picking remained unaddressed despite causing significant distress.
- We assessed our patient's skin-picking severity and impairment by using the Skin-Picking Scale-Revised<sup>4</sup>.
   His symptoms severity, impairment, and total scores were 14, 13, and 27, respectively.
- He was started on oral N-acetylcysteine 1200 mg once daily and was scheduled for follow-up visits where his SPS-R scores and potential need for dosage increase would be assessed.
- At a follow-up telephone interview 1 week after the initiation of N-acetylcysteine therapy, our patient denied improvement in his skin-picking with the starting dose. A higher dose and/or longer trial is planned to see if he may eventually respond to Nacetylcysteine.
- He will continue to have regular follow-ups.



## COLLEGE OF MEDICINE AND LIFE SCIENCES

THE UNIVERSITY OF TOLEDO





#### Discussion

- In previous reports of patients with skin-picking disorder and without comorbid psychosis, a beneficial effect was found once an antipsychotic was augmented with an SSRI or SNRI. These combined regimens were with paliperidone and fluoxetine, and with aripiprazole and venlafaxine. The success of one case was attributed to targeting of a hyposerotonergic, hyperdopaminergic corticostriatothalamic circuit<sup>5,7</sup>.
- Antagonism of D<sub>2</sub> receptors with various antipsychotic drugs has a role and there are reports that is effective, however, as mentioned this has not proven beneficial for the skin-picking behavior of our patient with schizoaffective disorder. At one time he was being treated with both an antipsychotic and SSRI (trazadone), yet he was still picking his skin at that time.
- We felt that a combined approach using D<sub>2</sub> antagonism and glutamate modulation with antipsychotics and N-acetylcysteine might prove useful, as both approaches have been reported to help with schizophrenia and skin-picking behavior<sup>8,9</sup>. Our patient reported no benefit after 1 week at the low dose of 1200 mg daily, however, this may not represent an adequate trial.
- Medication adherence is a unique factor in the management of patients with psychotic disorders, as high rates of nonadherence in these patients has been attributed to lack of insight, medication beliefs, and substance abuse<sup>10</sup>. The tolerability and safety of N-acetylcysteine was a factor in our choice; however, a future trial of fluoxetine alongside D<sub>2</sub> antagonism may be considered to address the proposed hyposerotonergic axis.

#### Conclusion

- Improvement in skin-picking behaviors has been seen in patients treated with SSRIs, antipsychotics, or N-acetylcysteine. However, some cases required dual therapy; and in our literature review we have not encountered any case reports describing a benefit or specific approach to patients who a comorbid psychotic disease.
- The pathophysiology of skin-picking behavior may prove to be different in patients with a comorbid psychotic disorder. The
  occurrence of SPD with psychosis may be under-recognized. Additional case reports and clinical trials are needed to further
  determine which pharmacologic regimen may best benefit skin-picking patients with psychosis.
- Our next step is to coordinate with IRB to design a clinical trial that screens for SPD in our patients with psychotic disorders, followed by intervention as appropriate.
- The symptom severity and distress caused by SPD was high in our patient. This case study demonstrates the importance prompt recognition and treatment of SPD in addition to treatment of Primary psychiatric diagnosis.

### References

- Mutasim DF, Adams BB. The psychiatric profile of patients with psychogenic excoriation. J Am Acad Dermatol. 2009;61(4):611-613.
   Leibovici V, Koran LM, Murad S, et al. Excoriation (skin-picking) disorder in adults: a cross-cultural survey of Israeli Jewish and Arab samples. Compr Psychiatry. 2015;58:102-107.
- 3. Arnold LM, Auchenbach MB, McElroy SL. Psychogenic excoriation. Clinical features, proposed diagnostic criteria, epidemiology and approaches to treatment. CNS Drugs. 2001;15(5):351-359.
- 4. Snorrason I, Ólafsson RP, Flessner CA, Keuthen NJ, Franklin ME, Woods DW. The Skin Picking Scale-Revised: Factor structure and. *Journal of Obsessive-Compulsive and Related Disorders*. 2012;1(2):133-137.
- 5. Spiegel DR, Finklea L. The recognition and treatment of pathological skin picking: a potential neurobiological underpinning of the efficacy of pharmacotherapy in impulse control disorders. Psychiatry (Edgmont). 2009;6(2):38-42. 6. Jafferany M, Patel A. Skin-Picking Disorder: A Guide to Diagnosis and Management. CNS Drugs. 2019.
- 7. Turner GA, Sutton S, Sharma A. Augmentation of Venlafaxine with Aripiprazole in a Case of Treatment-resistant Excoriation Disorder. Innov Clin Neurosci. 2014;11(1-2):29-31.
- 8. Sepehrmanesh Z, Heidary M, Akasheh N, Akbari H, Heidary M. Therapeutic effect of adjunctive N-acetyl cysteine (NAC) on symptoms of chronic schizophrenia: A double-blind, randomized clinical trial. Prog Neuropsychopharmacol Biol Psychiatry. 2018;82:289-296.
- 9. Deepmala, Slattery J, Kumar N, et al. Clinical trials of N-acetylcysteine in psychiatry and neurology: A systematic review. Neurosci Biobehav Rev. 2015;55:294-321.
- 10. Higashi K, Medic G, Littlewood KJ, Diez T, Granström O, De Hert M. Medication adherence in schizophrenia: factors influencing adherence and consequences of nonadherence, a systematic literature review. Therapeutic advances in psychopharmacology. 2013;3(4):200-218.